Skip to main content
. 2020 Jul 21;11(29):2847–2862. doi: 10.18632/oncotarget.27675

Figure 1. Mutant Kras-related chemoresistance is associated with increased expression of lncRNA PCAT-1 in metastatic lung cancer.

Figure 1

(A) Relative PCAT-1 expression levels in early stage (I-II) lung cancer and late metastatic (III-IV) tumor stage using RT-PCR. (B) Relative expression of PCAT-1 in Kras wild type (WT) and mutant (MT) lung cancer patients. (C) Kaplan-Meier curves of the survival rate of lung cancer patients in groups of PCAT-1 high or low expression levels. (D) Relative expression of PCAT-1 in chemoresistant or chemonaive cancer patients. (E) Percentage rates of PCAT-1 expression from primary lung cancer or lymph node metastasis biopsy tissues from Kras (WT/MT) patients. The results represent the mean ± SD of three independent experiments. Differences were considered statistically significant at p < 0.05. Statistically significant data are indicated by asterisks (* P < 0.05, ** P < 0.01).